Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late

被引:20
作者
Basak, Grzegorz W. [1 ]
Mikala, Gabor [2 ]
Koristek, Zdenek [3 ]
Jaksic, Ozren [4 ]
Basic-Kinda, Sandra [5 ]
Cegledi, Andrea [2 ]
Reti, Marienn [2 ]
Masszi, Tamas [2 ]
Mayer, Jiri [3 ]
Giebel, Sebastian [6 ]
Huebel, Kai [7 ]
Labar, Boris [5 ]
Wiktor-Jedrzejczak, Wieslaw [1 ]
机构
[1] Med Univ Warsaw, Dept Hematol Oncol & Internal Dis, PL-02097 Warsaw, Poland
[2] St Laszlo Hosp Budapest, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary
[3] Masaryk Univ Hosp, Dept Internal Med, Brno, Czech Republic
[4] Univ Hosp Dubrava, Dept Hematol, Zagreb, Croatia
[5] Univ Hosp Ctr Zagreb, Dept Hematol, Zagreb, Croatia
[6] Maria Sklodowska Curie Mem Inst Gliwice Branch, Ctr Comprehens Canc, Dept Bone Marrow Transplantat, Gliwice, Poland
[7] Univ Hosp Cologne, Cologne, Germany
关键词
Stem cell mobilization; plerixafor; autologous stem cell transplantation; G-CSF; COLONY-STIMULATING FACTOR; MULTIPLE-MYELOMA; CXCR4; ANTAGONIST; COLLECTION; AMD3100; TRANSPLANTATION; STRATEGIES; VOLUNTEERS;
D O I
10.3109/10428194.2011.578312
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 x 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 x 10(6) CD34+ cells/kg. Patients to whom plerixafor was administered late (>= 15 days) after chemotherapy, after a long duration (>= 13 days) of treatment with G-CSF, or when the white blood cell count was high (>= 20 x 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (53/mL) and those with higher concentrations. These data suggest that late administration of plerixafor in the course of chemotherapy-based mobilization does not contribute to the failure of this strategy.
引用
收藏
页码:1711 / 1719
页数:9
相关论文
共 18 条
[1]   Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience [J].
Basak, Grzegorz Wladyslaw ;
Knopinska-Posluszny, Wanda ;
Matuszak, Magdalena ;
Kisiel, Elzbieta ;
Hawrylecka, Dorota ;
Szmigielska-Kaplon, Anna ;
Urbaniak-Kujda, Donata ;
Dybko, Jaroslaw ;
Zielinska, Patrycja ;
Dabrowska-Iwanicka, Anna ;
Werkun, Joanna ;
Rzepecki, Piotr ;
Wroblewska, Wiktoria ;
Wiktor-Jedrzejczak, Wieslaw .
ANNALS OF HEMATOLOGY, 2011, 90 (05) :557-568
[2]  
Basak GW, 2010, ANN TRANSPL, V15, P61
[3]   Improving stem cell mobilization strategies: future directions [J].
Bensinger, W. ;
DiPersio, J. F. ;
McCarty, J. M. .
BONE MARROW TRANSPLANTATION, 2009, 43 (03) :181-195
[4]  
Burgstaler E., 2003, CYTOTHERAPY, V5, P446
[5]  
Burgstaler E., 2002, J CLIN APHER, V17, P148
[6]   The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF [J].
D'Addio, A. ;
Curti, A. ;
Worel, N. ;
Douglas, K. ;
Motta, M. R. ;
Rizzi, S. ;
Dan, E. ;
Taioli, S. ;
Giudice, V. ;
Agis, H. ;
Kopetzky, G. ;
Soutar, R. ;
Casadei, B. ;
Baccarani, M. ;
Lemoli, R. M. .
BONE MARROW TRANSPLANTATION, 2011, 46 (03) :356-363
[7]   The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil) [J].
De Clercq, Erik .
BIOCHEMICAL PHARMACOLOGY, 2009, 77 (11) :1655-1664
[8]   Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data [J].
Duarte, R. F. ;
Shaw, B. E. ;
Marin, P. ;
Kottaridis, P. ;
Ortiz, M. ;
Morante, C. ;
Delgado, J. ;
Gayoso, J. ;
Goterriz, R. ;
Martinez-Chamorro, C. ;
Mateos-Mazon, J. J. ;
Ramirez, C. ;
de la Rubia, J. ;
Achtereekte, H. ;
Gandhi, P. J. ;
Douglas, K. W. ;
Russell, N. H. .
BONE MARROW TRANSPLANTATION, 2011, 46 (01) :52-58
[9]   Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization [J].
Dugan, M. J. ;
Maziarz, R. T. ;
Bensinger, W. I. ;
Nademanee, A. ;
Liesveld, J. ;
Badel, K. ;
Dehner, C. ;
Gibney, C. ;
Bridger, G. ;
Calandra, G. .
BONE MARROW TRANSPLANTATION, 2010, 45 (01) :39-47
[10]   Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma [J].
Gertz, M. A. ;
Kumar, S. K. ;
Lacy, M. Q. ;
Dispenzieri, A. ;
Hayman, S. R. ;
Buadi, F. K. ;
Dingli, D. ;
Gastineau, D. A. ;
Winters, J. L. ;
Litzow, M. R. .
BONE MARROW TRANSPLANTATION, 2009, 43 (08) :619-625